Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Infection
97%
Pandemic
87%
Mycobacterium Bovis BCG
68%
Disease
65%
Placebo
64%
Prevalence
53%
HIV
50%
Observational Study
39%
BCG Vaccine
33%
Mycoplasma genitalium
33%
Chronic Disease
33%
Coronavirinae
33%
Randomized Clinical Trial
33%
Messenger RNA
33%
Influenza Vaccine
30%
SARS Coronavirus
21%
Vaccinia
20%
Live Vaccine
17%
Virus Infection
16%
Table Salt
16%
Cytokine
15%
Clinical Trial
8%
Chemotherapy
8%
Intervention Trial
8%
Mycobacterium Tuberculosis
8%
Immune Deficiency
8%
Bacterial Infection
8%
Adverse Event
8%
Prednisone
8%
Mucocutaneous Lymph Node Syndrome
8%
Inflammation
8%
Skin Manifestation
8%
mRNA Vaccine
8%
Severe Acute Respiratory Syndrome
6%
Vaccinia Vaccine
6%
Cross-Sectional Study
6%
Medicine and Dentistry
COVID-19
85%
Health Care
78%
Mycobacterium Bovis BCG
68%
Infection
56%
Immune System
50%
Human Immunodeficiency Virus
42%
Placebo
36%
Mycoplasma genitalium
33%
Prevalence
33%
Randomized Controlled Trial
33%
BCG Vaccine
33%
Randomized Clinical Trial
33%
Messenger RNA
33%
Influenza Vaccine
30%
Hazard Ratio
20%
Disease
17%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Study Participant
14%
Virus Infection
13%
Table Salt
13%
Influenza Vaccination
10%
Cumulative Incidence
9%
Clinical Trial
8%
Cross Reaction
8%
Kawasaki Disease
8%
Serositis
8%
Skin Manifestation
8%
Sequela
8%
mRNA Vaccine
8%
Secretion (Process)
8%
Live Vaccine
6%
Immunity
6%
Immunocompetent Cell
6%
Observational Study
6%
